QCRI Frontiers of Cancer Research presentation by Dr. Tamara Jamaspishvili
Event Start: May 03, 2018 4:00 pm
Location: QCRI 100/01 Conf Rms
a Frontiers of Cancer Research Presentation!
Thursday 03 May/18 at 4:00 pm in QCRI 100/01 Conf Rms
Tamara Jamaspishvili, MD, PhD
Division of Cancer Biology & Genetics (Dr. David Berman's lab)
"Importance of quantitative assessment of PTEN loss in clinical decision making"
Prostate cancer is a multifocal and multiclonal disease, resulting in diagnostic sampling errors and errors in risk assessment that lead to inappropriate treatment decisions. These issues are particularly acute in low and intermediate risk patients, who face the difficult decision of whether to be treated or monitored without intervention (active surveillance). The prognostic significance of PTEN loss (i.e., inactivation of the PTEN tumour suppressor gene) has been well established in prostate cancer. PTEN loss along with other biomarkers such as upregulation of ERG, SPINK1 form the basis of proposed prostate cancer subtypes that may vary in aggressiveness. The degree of PTEN loss within each cancer is variable, yet there is limited information on how this variation correlates with aggressiveness. In large, well annotated independent prostate cancer cohorts, we applied a variety of strategies to quantitatively measure PTEN loss and found for the first time that degree of loss is a highly significant factor. With further development, quantitative assessment of PTEN loss may become part of risk assessment in the diagnostic workup of men with low and intermediate risk prostate cancer.
Everyone is welcome!